Compare Rituximab vs Tecfidera head-to-head with other drugs for uses, ratings, cost, side effects and interactions.

15 июл. 2022 г. · Multiple sclerosis (MS) patients treated with rituximab were more than five times less likely to experience a relapse compared with patients given Tecfidera.

RIFUND-MS provides evidence that rituximab given as 1000 mg followed by 500 mg every 6 months is superior to dimethyl fumarate in preventing relapses over 24 ...

In summary, findings from the RIFUND-MS trial suggest that initiation of rituximab is superior to dimethyl fumarate for remaining free of relapse over 24 months ...

15 июл. 2022 г. · New Study Suggests Rituximab Reduces Relapses Better than Dimethyl Fumarate in Swedish Population of People with MS · About Multiple Sclerosis.

16 нояб. 2021 г. · This study reports real-world evidence of equivalent relapse outcomes between dimethyl fumarate and fingolimod and relapse reduction in favor of rituximab ...

11 авг. 2020 г. · Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera ( ...

8 янв. 2018 г. · Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS.

10 авг. 2023 г. · Rituximab should be considered as both a first- and second-line therapy option for most MS patients with active, non-progressive disease. DISEASE-MODIFYING... · RITUXIMAB · CONCLUSIONS

22 окт. 2024 г. · Conclusions and Relevance Rituximab was superior to all other DMT in terms of drug discontinuation and displayed better clinical efficacy ...